Cambridge, MA – According to filings with the U.S. Securities and Exchange Commission, Design Pharmaceuticals is raising $3,000,000.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Dirk Loeffert played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Design Pharmaceuticals
Design Pharma has a unique suite of proprietary and unrivaled technologies that enable rapid discovery and biosynthetic production of drug candidates at unprecedented scale: Droplet microfluidics for single-cell screening provides access to the universe of molecular biosynthesis encoded in living cells at a higher throughput than any other method; our multiplex GPCR assay platform screens drugs at scales enabled by next-generation sequencing (NGS); our engineering-inspired cell-free biosynthesis rapidly builds compounds to test chemical structures and the many variations thereof generated by our platform; and machine learning helps us biosynthesize better drug candidates. Our novel integrated platform is not only ideal for small molecule drug candidate discovery and lead optimization, but also offers new opportunities for live biotherapeutics (LBP) and biologics. We collaborate with pharmaceutical and biotech companies to harness natures chemistry for drug-like molecules and develop breakthrough therapeutics. Working together – winning together.

To learn more about Design Pharmaceuticals, visit http://www.designpharmaceuticals.com/

Contact:
Dirk Loeffert, Chief Executive Officer
617-553-1402
https://www.linkedin.com/in/dirk-loeffert-6267b57/

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved